Unither's acquisition in China
Unither Pharmaceuticals initiated the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd., a Chinese pharmaceutical company.
Paris (France) and Nanjing (China), August 25th, 2020 – Unither Pharmaceuticals, a global leader in sterile single dose technology, initiated today the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd, a Chinese pharmaceutical company. With this acquisition, Unither is accelerating the development of its business in China, the second largest market in the world, and complementing the worldwide Unither industrial footprint in Europe, the US and Brazil. “We are delighted to welcome this company into our group. Nanjing Ruinian Best will allow us to speed up our development and strengthen our activities in China, in line with our strategy to manufacture drugs closer to our customers” said Eric Goupil, Group President of Unither. This acquisition will allow Unither to support both Chinese and international pharmaceutical customers active in the ophthalmology and respiratory markets in China, and to offer them expertise in drug formulation and the manufacturing of sterile preservative-free single dose drugs.
About Nanjing Ruinian Best Pharmaceutical Co. Ltd,
Nanjing Ruinian Best Pharmaceutical Co. Ltd (NRB) specializes in the development and production of solid and liquid form pharmaceutical products, with an annual revenue around EUR 10 million. It is based in Nanjing, Jiangsu Province, and has 130 employees. It is owned by Wuxi Jinyuan Industrial Investment Development Group Co. Ltd, an investment holding company located in Binhu district, in Wuxi.
About Unither Pharmaceuticals
Founded in Amiens, France, in 1993, Unither Pharmaceuticals has become the worldwide leader in drug manufacturing for leading and generic pharmaceutical companies including but not limited to, eye drop and respiratory unit doses, saline solutions, and stick packs. In March 2017, Unither was acquired by Private Equity firms Ardian, Keensight Capital and Parquest Capital, as part of a Leverage Buy-Out operation conducted with the management team.
Unither Pharmaceuticals has 6 manufacturing sites and 1 R&D center located in France, the United States and Brazil. These sites generated a revenue of € 319 million in 2019 with a headcount exceeding 1,500 employees. With the completion of this acquisition, Unither will further strengthen its position as the global leader in sterile single doses produced with Blow- Fill-Seal (BFS) technology.
